DS
IMPL

David Shaw’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

David Shaw’s Portfolio IMPL Stock Details IMPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-27,142
Closed -$240K – 5338
2021
Q2 		$240K Buy
+27,142
New +$324K ﹤0.01% 4386

Other funds holding IMPL

KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
NVPX
Norwest Venture Partners XIV Palo Alto, California $60.4M AUM 9.56% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

David Shaw's IMPL Position: Q3 2021 in Review

David Shaw sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q3 2021, closing a stake of 27,142 shares — an estimated $240K sold.

David Shaw first reported a position in IMPL in Q2 2021 and held it in 1 quarter. The position peaked at $240K in Q2 2021. 44 funds tracked by Wall St. Rank hold IMPL as of Q3 2021.

  • David Shaw reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • David Shaw sold 27,142 Impel Pharmaceuticals Inc. Common Stock shares in Q3 2021, an estimated $240K.
  • David Shaw first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • David Shaw's Impel Pharmaceuticals Inc. Common Stock position peaked at $240K in Q2 2021.
  • 44 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q3 2021.

Based on D.E. Shaw & Co's 13F filing for Q3 2021, filed 15 Nov 2021.